Magle Chemoswed Holding Future Growth

Future criteria checks 6/6

Magle Chemoswed Holding is forecast to grow earnings and revenue by 72.2% and 27.6% per annum respectively. EPS is expected to grow by 62.8% per annum. Return on equity is forecast to be 21% in 3 years.

Key information

72.2%

Earnings growth rate

62.8%

EPS growth rate

Life Sciences earnings growth	25.8%
Revenue growth rate	27.6%
Future return on equity	21.0%
Analyst coverage	Low
Last updated	22 Jul 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:52X - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	379	51	70	85	1
12/31/2025	351	37	51	66	1
12/31/2024	250	9	-3	15	1
6/30/2024	179	8	-11	7	N/A
3/31/2024	171	12	3	18	N/A
12/31/2023	171	12	0	15	N/A
9/30/2023	170	10	3	21	N/A
6/30/2023	158	9	1	18	N/A
3/31/2023	155	8	-6	15	N/A
12/31/2022	148	9	-4	12	N/A
9/30/2022	138	10	0	13	N/A
6/30/2022	136	10	-4	13	N/A
3/31/2022	133	7	5	17	N/A
12/31/2021	132	4	14	26	N/A
9/30/2021	137	3	-19	-4	N/A
6/30/2021	133	1	-2	7	N/A
3/31/2021	134	2	-21	-9	N/A
12/31/2020	142	2	-18	-6	N/A
9/30/2020	151	14	-48	-18	N/A
6/30/2020	140	8	-64	-25	N/A
3/31/2020	137	1	-52	-2	N/A
12/31/2019	132	1	-62	-7	N/A
12/31/2018	110	-3	-10	11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 52X's forecast earnings growth (72.2% per year) is above the savings rate (0.8%).

Earnings vs Market: 52X's earnings (72.2% per year) are forecast to grow faster than the German market (20.2% per year).

High Growth Earnings: 52X's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 52X's revenue (27.6% per year) is forecast to grow faster than the German market (5.4% per year).

High Growth Revenue: 52X's revenue (27.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 52X's Return on Equity is forecast to be high in 3 years time (21%)

Magle Chemoswed Holding Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Recent updates

Second quarter 2024 earnings released: EPS: kr0.015 (vs kr0.43 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 18%

First quarter 2024 earnings released: EPS: kr0.27 (vs kr0.27 in 1Q 2023)

Magle Chemoswed Holding AB (publ) (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (publ) (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.

Full year 2023 earnings released: EPS: kr1.13 (vs kr0.85 in FY 2022)

Magle Chemoswed Holding AB (publ) to Report Q4, 2024 Results on Feb 26, 2025

New minor risk - Financial data availability

No independent directors

Investor sentiment improves as stock rises 17%

Now 24% undervalued

Investor sentiment improves as stock rises 20%

Full year 2022 earnings released: EPS: kr0.87 (vs kr0.39 in FY 2021)

Magle Chemoswed Holding AB 's Proprietary Product Axxo® Woundgel Receives Regulatory Approval in Kuwait

No independent directors

Magle Group's Vascular Embolic Product Embocept® S Receives Regulatory Approval in Argentina

Magle Group Appoints New Chief Marketing and Innovation Officer

Investor sentiment improved over the past week

Magle Chemoswed Holding AB Announces the Resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding

Magle Group Announces First Patients Enrolled in a Post-Market Study of Medical Device SmartPAN®

Magle Chemoswed Holding AB (publ) Announces Post Market Clinical Study for SmartPAN®

Magle Chemoswed Holding AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

No independent directors

Full year 2021 earnings released: EPS: kr0.39 (vs kr0.24 in FY 2020)

Magle Chemoswed Holding AB (publ), Annual General Meeting, May 17, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Magle Chemoswed Holding AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Full year 2020 earnings released: EPS kr0.24

Investor sentiment improved over the past week

Magle Chemoswed Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20 million.

New 90-day high: €3.60

New 90-day high: €3.28

Magle Chemoswed Holding AB (publ) to Report Fiscal Year 2020 Results on Apr 14, 2021

New 90-day high: €3.22

New 90-day high: €3.16

Magle Chemoswed Holding AB (Publ) Announces the Appointment of Joel Eklund as New Member of the Board

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies